MicroRNAs in melanoma development and resistance to target therapy

Luigi Fattore, Susan Costantini, Debora Malpicci, Ciro Francesco Ruggiero, Paolo Antonio Ascierto, Carlo M. Croce, Rita Mancini, Gennaro Ciliberto

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

microRNAs constitute a complex class of pleiotropic post-transcriptional regulators of gene expression involved in the control of several physiologic and pathologic processes. Their mechanism of action is primarily based on the imperfect matching of a seed region located at the 5' end of a 21-23 nt sequence with a partially complementary sequence located in the 3' untranslated region of target mRNAs. This leads to inhibition of mRNA translation and eventually to its degradation. Individual miRNAs are capable of binding to several mRNAs and several miRNAs are capable of influencing the function of the same mRNAs. In recent years networks of miRNAs are emerging as capable of controlling key signaling pathways responsible for the growth and propagation of cancer cells. Furthermore several examples have been provided which highlight the involvement of miRNAs in the development of resistance to targeted drug therapies. In this review we provide an updated overview of the role of miRNAs in the development of melanoma and the identification of the main downstream pathways controlled by these miRNAs. Furthermore we discuss a group of miRNAs capable to influence through their respective up- or down-modulation the development of resistance to BRAF and MEK inhibitors.

Original languageEnglish
Pages (from-to)22262-22278
Number of pages17
JournalOncotarget
Volume8
Issue number13
DOIs
Publication statusPublished - 2017

Fingerprint

MicroRNAs
Melanoma
Therapeutics
Messenger RNA
Mitogen-Activated Protein Kinase Kinases
Protein Biosynthesis
3' Untranslated Regions
Pathologic Processes
Regulator Genes
Seeds
Gene Expression
Drug Therapy
Growth
Neoplasms

Keywords

  • Drug resistance
  • Intracellular pathways
  • Melanoma
  • MiRNA
  • Target therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Fattore, L., Costantini, S., Malpicci, D., Ruggiero, C. F., Ascierto, P. A., Croce, C. M., ... Ciliberto, G. (2017). MicroRNAs in melanoma development and resistance to target therapy. Oncotarget, 8(13), 22262-22278. https://doi.org/10.18632/oncotarget.14763

MicroRNAs in melanoma development and resistance to target therapy. / Fattore, Luigi; Costantini, Susan; Malpicci, Debora; Ruggiero, Ciro Francesco; Ascierto, Paolo Antonio; Croce, Carlo M.; Mancini, Rita; Ciliberto, Gennaro.

In: Oncotarget, Vol. 8, No. 13, 2017, p. 22262-22278.

Research output: Contribution to journalReview article

Fattore, L, Costantini, S, Malpicci, D, Ruggiero, CF, Ascierto, PA, Croce, CM, Mancini, R & Ciliberto, G 2017, 'MicroRNAs in melanoma development and resistance to target therapy', Oncotarget, vol. 8, no. 13, pp. 22262-22278. https://doi.org/10.18632/oncotarget.14763
Fattore, Luigi ; Costantini, Susan ; Malpicci, Debora ; Ruggiero, Ciro Francesco ; Ascierto, Paolo Antonio ; Croce, Carlo M. ; Mancini, Rita ; Ciliberto, Gennaro. / MicroRNAs in melanoma development and resistance to target therapy. In: Oncotarget. 2017 ; Vol. 8, No. 13. pp. 22262-22278.
@article{5bf60c0de81d45c48b8bc9f9d4e7144b,
title = "MicroRNAs in melanoma development and resistance to target therapy",
abstract = "microRNAs constitute a complex class of pleiotropic post-transcriptional regulators of gene expression involved in the control of several physiologic and pathologic processes. Their mechanism of action is primarily based on the imperfect matching of a seed region located at the 5' end of a 21-23 nt sequence with a partially complementary sequence located in the 3' untranslated region of target mRNAs. This leads to inhibition of mRNA translation and eventually to its degradation. Individual miRNAs are capable of binding to several mRNAs and several miRNAs are capable of influencing the function of the same mRNAs. In recent years networks of miRNAs are emerging as capable of controlling key signaling pathways responsible for the growth and propagation of cancer cells. Furthermore several examples have been provided which highlight the involvement of miRNAs in the development of resistance to targeted drug therapies. In this review we provide an updated overview of the role of miRNAs in the development of melanoma and the identification of the main downstream pathways controlled by these miRNAs. Furthermore we discuss a group of miRNAs capable to influence through their respective up- or down-modulation the development of resistance to BRAF and MEK inhibitors.",
keywords = "Drug resistance, Intracellular pathways, Melanoma, MiRNA, Target therapy",
author = "Luigi Fattore and Susan Costantini and Debora Malpicci and Ruggiero, {Ciro Francesco} and Ascierto, {Paolo Antonio} and Croce, {Carlo M.} and Rita Mancini and Gennaro Ciliberto",
year = "2017",
doi = "10.18632/oncotarget.14763",
language = "English",
volume = "8",
pages = "22262--22278",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "13",

}

TY - JOUR

T1 - MicroRNAs in melanoma development and resistance to target therapy

AU - Fattore, Luigi

AU - Costantini, Susan

AU - Malpicci, Debora

AU - Ruggiero, Ciro Francesco

AU - Ascierto, Paolo Antonio

AU - Croce, Carlo M.

AU - Mancini, Rita

AU - Ciliberto, Gennaro

PY - 2017

Y1 - 2017

N2 - microRNAs constitute a complex class of pleiotropic post-transcriptional regulators of gene expression involved in the control of several physiologic and pathologic processes. Their mechanism of action is primarily based on the imperfect matching of a seed region located at the 5' end of a 21-23 nt sequence with a partially complementary sequence located in the 3' untranslated region of target mRNAs. This leads to inhibition of mRNA translation and eventually to its degradation. Individual miRNAs are capable of binding to several mRNAs and several miRNAs are capable of influencing the function of the same mRNAs. In recent years networks of miRNAs are emerging as capable of controlling key signaling pathways responsible for the growth and propagation of cancer cells. Furthermore several examples have been provided which highlight the involvement of miRNAs in the development of resistance to targeted drug therapies. In this review we provide an updated overview of the role of miRNAs in the development of melanoma and the identification of the main downstream pathways controlled by these miRNAs. Furthermore we discuss a group of miRNAs capable to influence through their respective up- or down-modulation the development of resistance to BRAF and MEK inhibitors.

AB - microRNAs constitute a complex class of pleiotropic post-transcriptional regulators of gene expression involved in the control of several physiologic and pathologic processes. Their mechanism of action is primarily based on the imperfect matching of a seed region located at the 5' end of a 21-23 nt sequence with a partially complementary sequence located in the 3' untranslated region of target mRNAs. This leads to inhibition of mRNA translation and eventually to its degradation. Individual miRNAs are capable of binding to several mRNAs and several miRNAs are capable of influencing the function of the same mRNAs. In recent years networks of miRNAs are emerging as capable of controlling key signaling pathways responsible for the growth and propagation of cancer cells. Furthermore several examples have been provided which highlight the involvement of miRNAs in the development of resistance to targeted drug therapies. In this review we provide an updated overview of the role of miRNAs in the development of melanoma and the identification of the main downstream pathways controlled by these miRNAs. Furthermore we discuss a group of miRNAs capable to influence through their respective up- or down-modulation the development of resistance to BRAF and MEK inhibitors.

KW - Drug resistance

KW - Intracellular pathways

KW - Melanoma

KW - MiRNA

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=85016434319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016434319&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.14763

DO - 10.18632/oncotarget.14763

M3 - Review article

VL - 8

SP - 22262

EP - 22278

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 13

ER -